Sophia Abene

CDPH advises consuming pasteurized milk, which kills the virus, while the state increases testing and monitoring following 29 confirmed human cases of H5N1 linked to infected dairy cows.

Using fecal microbiota transplantation within the CGA framework further enhanced survival and care efficiency.

Combining over 1,000 human antibodies, GIGA-2339 aims to achieve viral clearance and activate the immune system, offering a potential solution where current therapies fall short of providing a cure.

Recent studies show oral vancomycin reduces CDI by 64% in stem cell transplant patients, Biktarvy is effective for HIV/HBV co-infection, climate change drives rising dengue cases, and a 7-day antibiotic regimen is as effective as 14 days for bloodstream infections.

Wolverine Packing Co is recalling ground beef due to potential contamination with E coli O157:H7

Along with the CDC, we highlight the One Health approach and advocate for effective infection control measures, such as vaccination and innovative technologies, to prevent the spread of resistant pathogens and combat AMR.

Nicole M Iovine discusses the risks associated with this particular E coli strain, challenges posed by organic farming, and offers practical food safety tips to protect vulnerable populations.

The BALANCE trial suggests that shorter treatment durations may reduce healthcare costs, antibiotic exposure, and antimicrobial resistance risk, providing an alternative for critically ill patients.

California reports a suspected case of a child; Oregon's first human case linked to a poultry outbreak; and Canada's first locally acquired case in a critically ill teen.

The ALLIANCE Phase III study demonstrated that Biktarvy, a TAF-based regimen, achieved sustained virologic suppression in adults with HIV/HBV co-infection.

In recognition of C difficile Awareness Month this November, the CDC's 2023 HAI Progress Report highlights continued progress in reducing CDIs across US healthcare settings.

Reduction of in-hospital rate of C difficile infection from 11% to 4%, with no increased risk of infection following treatment.

Arbutus CEO Michael McElhaugh discussed trial results showing that a combination of imdusiran, an RNAi therapeutic, and pegylated interferon alfa-2α can achieve a functional cure in chronic hepatitis B patients.

Grimmway Farms issued a voluntary recall after 26 out of 27 individuals interviewed as part of the outbreak investigation reported eating their carrots before becoming ill.

This week, food recalls due to Listeria monocytogenes contamination and, a study comparing treatments for recurrent C difficile infections underscore the need for further research, policy adjustments, and more.

With up to 37.5% of children carrying this resistance mutation the findings suggest that current treatment protocols may be losing effectiveness.

Medication errors and patient falls in COVID-19-positive and non-COVID-19 patients highlight the impact of hospital workload on patient safety.

Participants who used fentanyl were 1.64 times more likely to experience HCV seroconversion compared to those who did not.

17 randomized controlled trials involving 4,148 patients assessed the efficacy of various treatments, finding that fecal microbiota transplantation via the lower gastrointestinal route was the most effective.

Results suggest a shorter treatment duration could reduce costs and improve access in low- and middle-income countries.

Chad Costley, MD, MPH, discussed the platform's ability to respond to emerging respiratory diseases and the challenges in advancing mucosal vaccine development for health preparedness.

Chad Costley, MD, MBA, provided an update on BlueWillow Biologics' NanoVax intranasal vaccine for H5N1, with Phase 1 trial data showing broad immune responses and no serious adverse events.

Affected products include Taiwan Enoki mushrooms, select soft-ripened cheeses, and Autumn Turkey Sandwiches.

Findings from the CAPELLA study reveal virologic suppression and a safety profile for multidrug-resistant HIV-1.

The combination of the antiviral agents islatravir and lenacapavir demonstrates both efficacy and safety, leading to advancement into Phase 3 trials.

From improving infection control and antibiotic stewardship, identifying RT 027 as a risk factor for vancomycin resistance in C diff, developing a universal flu vaccine, better management for drug-resistant pathogens, and more.

Despite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.

This composite peptide vaccine targets key bacterial toxins to prevent sepsis, enhance antibiotic efficacy, reduce inflammation in diseases and cancer, with further data expected soon.

A five-year study highlights high virologic suppression and well-tolerated treatment in black patients.

A study of carbapenemase-producing organisms found similar rates of infections, highlighting treatment challenges, the role of rapid diagnostics, and surveillance on antimicrobial stewardship due to high mortality rates.